In August 2021, we established an ESG (Environmental, Social and Governance) committee to supervise the ESG strategies, policies, long-term sustainability objectives and risks of the company.
In the same year, we achieved BBB Rating by the MSCI ESG assessment, the highest newly initiated rating among China-based biotech companies.
In February 2023, we received an “A” Rating from MSCI ESG, a testament to our commitment to the highest ESG standards.
Our commitment to ESG can be summarized into three “P”s
Deliver novel products in immuno-oncology to bring transformational medicines to patients through innovation.Read More
A commitment to philanthropic giving which can help build stronger communities.Read More
Create a diverse and inclusive culture by promoting gender equity, and supporting employees’ personal and career development.Read More